Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (8.290.694 €): PharmaLedger Hor 01.01.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

PharmaLedger

The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients. PharmaLedger will serve as a single source of truth for the healthcare ecosystem and will be designed for efficient decentralized governance, wide adoption by the stakeholders of the ecosystem, compliance with extant and emerging standards and regulation, and end-to-end connectivity and interoperability. Sustainability of the platform will be ensured by leveraging existing, successful blockchain technologies; open source reference implementation; and a fully documented, actionable methodology for evolutionary digitization of the healthcare industry. The project will address the key challenges of the healthcare ecosystem through prioritized delivery of applications and validation of business use cases, including but not be limited to end-to-end product tracking for combating counterfeit medicines and medical supplies; supply chain integrity; efficiency of recruitment and submission in clinical trials; and machine-learning health data marketplaces. The platform will support integrated use of medical devices across the use cases. The PharmaLedger project brings together 28 partners from 10 EU Member States, including 11 large pharmaceutical companies; highly innovative technology SMEs specializing in blockchain development, security, privacy and business intelligence; universities and research institutes specializing in pharmacoeconomic analysis, research of patient requirements, big data analytics and electronic health records; leading clinical trials companies; supply chain partners; patient representatives; and leading healthcare service providers.


Geförderte Unternehmen:

Firmenname Förderungssumme
Abbvie Inc. 0,00 €
Arteevo Technologies Ltd. 906.250 €
Astrazeneca AB 0,00 €
Bayer AG 0,00 €
Boehringer Ingelheim Internationalgesellschaft mbH 0,00 €
Dimokritio Panepistimio Thrakis 216.250 €
Ekon Modeling Sofware Systems Ltd.*Ekon 456.250 €
Ethniko Kentro Erevnas Kai Technologikis Anaptyxis 282.500 €
European Forum for Good Clinical Practice 103.750 €
F. Hoffmann-LA Roche AG 0,00 €
Forum des Patients Europeens 143.750 €
Glaxosmithkline Research & Development Ltd. 0,00 €
Imprensa Nacional - Casa da Moeda SA 365.625 €
Janssen Pharmaceutica N.V. 0,00 €
Katholieke Universiteit Leuven 338.500 €
Merck Sharp & Dohme Corp 0,00 €
National Research And Development Institute For Cryogenics And Isotopic Technologies Icsi RM Valcea 370.000 €
Novartis Pharma AG 0,00 €
Novo Nordisk A/S 0,00 €
Onorach Ltd. 511.569 €
Ospedale Pediatrico Bambino Gesu 347.500 €
PDM e FC Projecto Desenvolvimento Manutencao Formacao e Consultadoria SA 823.125 €
Pfizer Ltd. 0,00 €
Pharmaledger Association 1,00 €
Romsoft Srl 1.157.500 €
Technovative Solutions Ltd. 910.625 €
UCB Biopharma 0,00 €
Unidade Local de Saude do Alentejo Central ΕΠΕ 176.250 €
Universidad Politecnica de Madrid 873.749 €
Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat 307.500 €

Quelle: https://cordis.europa.eu/project/id/853992

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.